

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC., WATSON LABORATORIES, INC., DR. REDDY'S LABORATORIES,
INC., DR. REDDY'S LABORATORIES, LTD., and SUN
PHARMACEUTICALS INDUSTRIES LTD.,
Petitioners,

v.

MERCK SHARP & DOHME CORP.
Patent Owner.

Case IPR2020-00040¹
Patent 7,326,708

UNOPPOSED JOINT MOTION TO WITHDRAW JOINDER AS TO
PETITIONERS TEVA PHARMACEUTICALS USA, INC. AND WATSON
LABORATORIES, INC.

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

¹ Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. were joined as a party to this proceeding via Motion for Joinder in IPR2020-01045; Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. were joined as a party to this proceeding via a Motion for Joinder in IPR2020-01060; and Sun Pharmaceuticals Industries Ltd. was joined as a party to this proceeding via Motion for Joinder in IPR2020-01072.

Pursuant to the Board’s December 8, 2020 Termination Order in *Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. v. Merck Sharp & Dohme Corp.* (IPR2020-01045, Paper 25), Merck Sharp & Dohme Inc. (“Merck”) and Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. (collectively, “Teva”) respectfully submit this Unopposed Joint Motion to Withdraw Joinder as to Petitioners Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc.

I. STATEMENT OF PRECISE RELIEF REQUESTED

Merck and Teva respectfully request that the Board allow Teva to withdraw as Joinder Petitioner from this matter.

II. STATEMENT OF MATERIAL FACTS

1. On October 30, 2019, Mylan Pharmaceuticals Inc. (“Mylan”) filed a Petition for Inter Partes Review regarding U.S. Patent No. 7,326,708, owned by Merck. (IPR2020-00040, Paper 1)
2. On May 12, 2020, the Board instituted this trial based on that petition. (IPR2020-00040, Paper 21).
3. On June 10, 2020, Teva filed a Petition for Inter Partes Review (IPR2020-01045, Paper 3) that was substantively identical to the petition filed by Mylan, as well as a Motion for Joinder, seeking to be joined to the IPR filed by Mylan (IPR2020-01045, Paper 4).

4. On September 1, 2020, the Board instituted Teva's petition and granted the motion for joinder. (IPR2020-01045, Paper 21). On that same date, the Board granted similar motions for joinder filed by Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collective, "DRL") and Sun Pharmaceuticals Industries Ltd. ("Sun"). (IPR2020-01045, Paper 21 at 13).

5. On November 24, 2020, Merck and Teva filed a Joint Motion to Terminate IPR2020-01045 as a result of a settlement between the parties. (IPR2020-01045, Paper 22).

6. On December 8, 2020, the Board terminated IPR2020-01045. (IPR2020-01045, Paper 25).

III. ARGUMENT

Teva and Merck respectfully submit that in view of the Board's Termination Decision in IPR2020-01045, Teva should be permitted to withdraw as a joinder petitioner from this matter. Counsel for petitioners Mylan, DRL, and Sun have indicated Mylan, DRL and Sun do not oppose this motion.

IV. CONCLUSION

For the reasons stated above, Merck and Teva respectfully request that petitioners Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. be withdrawn as Joinder Petitioners in this matter.

Case IPR2020-00040
Patent No. 7,326,708

Date: December 15, 2020

Respectfully submitted,

/Stanley E. Fisher/

Stanley E. Fisher (Reg. No. 55,820)
Bruce R. Genderson (*Pro Hac Vice*)
David M. Krinsky (Reg. No. 72,339)
Elise M. Baumgarten (*Pro Hac Vice*)
Alexander S. Zolan (*Pro Hac Vice*)
Shaun P. Mahaffy (Reg. No. 75,534)
Anthony H. Sheh (Reg. No. 70,576)
WILLIAMS & CONNOLLY LLP
725 Twelfth Street, N.W.
Washington, DC 20005
T: (202) 434-5000
F: (202) 434-5029
sfisher@wc.com
bgenderson@wc.com
dkrinsky@wc.com
ebaumgarten@wc.com
azolan@wc.com
smahaffy@wc.com
asheh@wc.com

*Counsel for Patent Owner
Merck Sharp & Dohme Corp.*

/Keith A. Zullo/

Keith A. Zullo (Reg. No. 37,975)
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
Tel: 212-813--8800
Fax: 212-355-3333
kzullo@goodwinlaw.com

Counsel for Petitioners Teva

Case IPR2020-00040
Patent No. 7,326,708

*Pharmaceuticals USA, Inc. and
Watson Laboratories, Inc.*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.